Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $39 million versus the consensus estimate of $40.69 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.